LP-211: Difference between revisions

Page 1
Page 2
Content deleted Content added
No edit summary
 
(16 intermediate revisions by 13 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 449685788
| IUPAC_name = N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide
| IUPAC_name = N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide
| image = LP-211_structure.png
| image = LP-211_structure.png
Line 14: Line 17:
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 21: Line 24:
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number =
| CAS_number = 1052147-86-0
| ATC_prefix =
| ATC_prefix =
| ATC_suffix =
| ATC_suffix =
| PubChem = 25107716
| PubChem = 25107716
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 23343345
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NCS2VAH93R


<!--Chemical data-->
<!--Chemical data-->
| C=30 | H=34 | N=4 | O=1
| C=30 | H=34 | N=4 | O=1
| molecular_weight = 466.616 g/mol
| smiles = N#Cc3ccc(cc3)CNC(=O)CCCCCN(CC2)CCN2c1ccccc1-c4ccccc4
| smiles = N#Cc3ccc(cc3)CNC(=O)CCCCCN(CC2)CCN2c1ccccc1-c4ccccc4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C30H34N4O/c31-23-25-14-16-26(17-15-25)24-32-30(35)13-5-2-8-18-33-19-21-34(22-20-33)29-12-7-6-11-28(29)27-9-3-1-4-10-27/h1,3-4,6-7,9-12,14-17H,2,5,8,13,18-22,24H2,(H,32,35)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = BQEDZLDNNBDKDS-UHFFFAOYSA-N

}}
}}


'''LP-211''' is a drug which acts as a potent and selective [[agonist]] at the [[5-HT7 receptor|5HT<sub>7</sub>]] [[serotonin]] [[Receptor (biochemistry)|receptor]], with better brain penetration than older 5-HT<sub>7</sub> agonists in the same series, and similar effects in animals.<ref name="pmid20600619">{{cite journal |author=Hedlund PB, Leopoldo M, Caccia S, Sarkisyan G, Fracasso C, Martelli G, Lacivita E, Berardi F, Perrone R |title=LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor |journal=Neuroscience Letters |volume=481 |issue=1 |pages=12–6 |year=2010 |month=August |pmid=20600619 |pmc=2910240 |doi=10.1016/j.neulet.2010.06.036 |url=}}</ref><ref name="pmid21459634">{{cite journal |author=Monti JM |title=Serotonin control of sleep-wake behavior |journal=Sleep Medicine Reviews |volume=15 |issue=4 |pages=269–81 |year=2011 |month=August |pmid=21459634 |doi=10.1016/j.smrv.2010.11.003 |url=}}</ref>
'''LP-211''' is a drug which acts as a potent and selective [[agonist]] at the [[5-HT7 receptor|5HT<sub>7</sub>]] [[serotonin receptor]], with better brain penetration than older 5-HT<sub>7</sub> agonists in the same series, and similar effects in animals.<ref name="pmid20600619">{{cite journal |vauthors=Hedlund PB, Leopoldo M, Caccia S, Sarkisyan G, Fracasso C, Martelli G, Lacivita E, Berardi F, Perrone R |title=LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor |journal=Neuroscience Letters |volume=481 |issue=1 |pages=12–6 |date=August 2010 |pmid=20600619 |pmc=2910240 |doi=10.1016/j.neulet.2010.06.036 }}</ref><ref name="pmid21459634">{{cite journal |author=Monti JM |title=Serotonin control of sleep-wake behavior |journal=Sleep Medicine Reviews |volume=15 |issue=4 |pages=269–81 |date=August 2011 |pmid=21459634 |doi=10.1016/j.smrv.2010.11.003 }}</ref>


==See also==
==See also==
Line 44: Line 55:


==References==
==References==
{{reflist}}
{{Reflist}}


{{Serotonin receptor modulators}}
{{Serotonergics}}
{{Piperazines}}


[[Category:Serotonin receptor agonists]]
[[Category:5-HT7 agonists]]
[[Category:Piperazines]]